AstraZeneca PLC (AZN)

NASDAQ: AZN · Real-Time Price · USD
81.69
-0.42 (-0.51%)
Sep 4, 2025, 2:37 PM - Market open
-0.51%
Market Cap254.65B
Revenue (ttm)56.50B
Net Income (ttm)8.30B
Shares Out 1.55B
EPS (ttm)5.31
PE Ratio15.39
Forward PE16.90
Dividend$1.54 (1.88%)
Ex-Dividend DateAug 8, 2025
Volume2,174,189
Open81.88
Previous Close82.11
Day's Range81.48 - 82.28
52-Week Range61.24 - 85.99
Beta0.15
AnalystsStrong Buy
Price Targetn/a
Earnings DateJul 29, 2025

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
IPO Date May 12, 1993
Employees 92,900
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial Statements

News

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

1 day ago - Reuters

Final Trades: AstraZeneca, Corning, the IBIT and the SPHD

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: GLWIBITSPHD
1 day ago - CNBC Television

AstraZeneca: Buy This Pharma Star Now For Upside Potential

Since last month, AstraZeneca's shares have trounced the S&P 500 index. The drugmaker has an impressive drug portfolio and a deep pipeline, which should continue to drive core EPS growth for the fores...

2 days ago - Seeking Alpha

AstraZeneca to seek approval for blood pressure drug by year-end

AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugmaker...

5 days ago - Reuters

Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMis...

14 days ago - Business Wire

The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact

The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J.

22 days ago - PRNewsWire

AstraZeneca: Great Portfolio, But Not A Great Price

AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomir...

24 days ago - Seeking Alpha

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a...

Other symbols: SOPH
4 weeks ago - PRNewsWire

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

4 weeks ago - WSJ

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

4 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

4 weeks ago - CNBC Television

European drugmakers fall after Trump raises stakes over US drug price cuts

Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...

Other symbols: MRKNVOSNY
4 weeks ago - Reuters

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...

4 weeks ago - Forbes

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.

4 weeks ago - CNBC Television

Trump pressures 17 pharma CEOs to cut US drug prices

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...

5 weeks ago - Reuters

Trump posts letters to 17 pharmaceutical companies about drug prices

CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.

5 weeks ago - CNBC Television

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...

5 weeks ago - CNBC

3 Of The Best SWANs On My Shopping List

Our picks for today are MercadoLibre, Vulcan Materials, and AstraZeneca, with each providing a mix of value and growth. MercadoLibre is Latin America's leading e-commerce and fintech platform with inc...

Other symbols: MELIVMC
5 weeks ago - Seeking Alpha

Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana

ACCRA, Ghana--(BUSINESS WIRE)-- #AfricaHealth--The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial...

5 weeks ago - Business Wire

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure

AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.

5 weeks ago - CNBC

AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript

AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Andrew P. Barnett - Head of Investor Relations Aradhana Sarin - CFO & Executive Director Da...

5 weeks ago - Seeking Alpha

AstraZeneca CEO: Medical innovation in China is surging

"What we have seen in China is really, a substantial return of scientists from the US, but also from the UK and elsewhere, but not because of policy, simply because they could see opportunities in Chi...

5 weeks ago - Bloomberg Markets and Finance

AstraZeneca CEO: If you manufacture locally, there's no need to increase prices

CNBC's Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the company's most recent quarter, investment in innovation in the U.S., whether tariffs could impact prices, and much more.

5 weeks ago - CNBC Television

AstraZeneca CEO doubles down on U.S. amid rumors of listing shift

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was "rapidly transferring manufacturing" across the Atlantic. "This country [the U.S.] wil...

5 weeks ago - CNBC

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc AZN on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by do...

5 weeks ago - Benzinga